| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
86,924,000 |
| Market
Cap: |
100.83(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.04 - $4.57 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 5.1 |
| Insider 6 Months : 10.9 |
| Insider 3/6 Months : 16.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
21,000 |
143,700 |
143,700 |
165,700 |
| Total Buy Value |
$29,373 |
$252,786 |
$252,786 |
$472,177 |
| Total People Bought |
1 |
5 |
5 |
7 |
| Total Buy Transactions |
1 |
5 |
5 |
7 |
| Total Shares Sold |
0 |
34,624 |
36,227 |
105,220 |
| Total Sell Value |
$0 |
$65,472 |
$70,570 |
$1,118,404 |
| Total People Sold |
0 |
3 |
3 |
9 |
| Total Sell Transactions |
0 |
4 |
5 |
17 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skvarka Jan |
Director |
– • – |
2025-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
57,603 |
207,154 |
|
- |
|
| Myers Scott Dunseth |
Director |
– • – |
2025-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
57,603 |
338,795 |
|
- |
|
| Walker Luke Nathaniel |
Director |
– • – |
2025-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
57,603 |
144,284 |
|
- |
|
| Johnson David Michael |
Director |
– • – |
2025-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
57,603 |
250,421 |
|
- |
|
| Kariuki Enoch |
Director |
– • – |
2025-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
57,603 |
137,365 |
|
- |
|
| Myers Scott Dunseth |
Director |
– • – |
2025-04-30 |
4 |
B |
$1.40 |
$29,373 |
D/D |
21,000 |
281,192 |
2.39 |
-17% |
|
| Bruns Ingmar |
Chief Medical Officer |
• – – |
2025-02-06 |
4 |
B |
$2.28 |
$45,656 |
D/D |
20,000 |
36,629 |
2.74 |
-31% |
|
| Bruns Ingmar |
Chief Medical Officer |
• – – |
2025-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,629 |
16,629 |
|
- |
|
| Paul Andrea |
Chief Legal Officer |
• – – |
2025-02-03 |
4 |
S |
$1.71 |
$22,643 |
D/D |
(13,230) |
1,070,784 |
|
13% |
|
| Paul Andrea |
Chief Legal Officer |
• – – |
2025-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
934,041 |
1,084,014 |
|
- |
|
| Vultaggio Vincent |
PAO and Interim PFO |
• – – |
2025-02-03 |
4 |
S |
$1.71 |
$4,476 |
D/D |
(2,615) |
189,826 |
|
13% |
|
| Vultaggio Vincent |
PAO and Interim PFO |
• – – |
2025-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
158,586 |
192,441 |
|
- |
|
| Eastland Julia Marie |
CEO & President |
• • – |
2025-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
59,388 |
87,888 |
|
- |
|
| Lackner Mark |
Chief Scientific Officer |
• – – |
2025-02-03 |
4 |
S |
$1.71 |
$24,591 |
D/D |
(14,368) |
512,856 |
|
13% |
|
| Lackner Mark |
Chief Scientific Officer |
• – – |
2025-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
335,907 |
527,224 |
|
- |
|
| Skvarka Jan |
Director |
– • – |
2025-01-31 |
4 |
B |
$1.72 |
$103,446 |
D/D |
60,000 |
149,551 |
2.39 |
-15% |
|
| Eastland Julia Marie |
CEO & President |
• • – |
2025-01-31 |
4 |
B |
$1.73 |
$49,345 |
D/D |
28,500 |
28,500 |
2.81 |
-15% |
|
| Walker Luke Nathaniel |
Director |
– • – |
2025-01-31 |
4 |
B |
$1.76 |
$24,966 |
D/D |
14,200 |
86,681 |
2.39 |
-15% |
|
| Lackner Mark |
Chief Scientific Officer |
• – – |
2025-01-02 |
4 |
S |
$3.12 |
$13,762 |
D/D |
(4,411) |
191,317 |
|
60% |
|
| Myers Scott Dunseth |
Director |
– • – |
2024-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
260,192 |
260,192 |
|
- |
|
| Vultaggio Vincent |
Principal Accounting Officer |
• – – |
2024-10-04 |
4 |
AS |
$3.18 |
$5,098 |
D/D |
(1,603) |
33,855 |
|
-28% |
|
| Johnson David Michael |
Director |
– • – |
2024-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
48,429 |
192,818 |
|
- |
|
| Skvarka Jan |
Director |
– • – |
2024-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
41,581 |
89,551 |
|
- |
|
| Kariuki Enoch |
Director |
– • – |
2024-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
41,581 |
79,762 |
|
- |
|
| Gallagher Cam |
President, Interim CFO |
• • – |
2024-05-31 |
4 |
AS |
$11.98 |
$114,972 |
D/D |
(9,597) |
633,680 |
|
- |
|
264 Records found
|
|
Page 1 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (1.69%) 
